Humacyte (HUMA) Hisse Özeti

Humacyte, Inc. iştirakleriyle birlikte, birden fazla terapötik alanda bir dizi anatomik konumdaki hastalıkların ve durumların tedavisi için kullanıma hazır, implante edilebilir ve biyomühendislik ürünü insan dokularının geliştirilmesi ve üretilmesiyle ilgilenmektedir. Daha fazla detay

HUMA temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Kazançların yılda 65.32% oranında artması öngörülüyor

Risk Analizi

Son 3 ayda hisse senedi fiyatı US piyasasına kıyasla oldukça dalgalı

1 yıldan az nakit akışı var

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Anlamlı bir geliri yok ( $2M )

HUMA Community Fair Values

Create Narrative

See what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

95.9% undervalued

AnalystHighTarget

4mo ago

Vascular Trauma And Dialysis Pipeline Will Transform Long Term Revenue Potential

259

88.2% undervalued

AnalystConsensusTarget

4mo ago

Bioengineered Vascular Tissue Platform Will Transform Trauma And Dialysis Care Over The Coming Years

Dialysis Access And Vascular Trauma Challenges Will Eventually Support A Stronger Long Term Outlook

Top Analyst Narratives

95.9% undervalued

AnalystHighTarget

4mo ago

Vascular Trauma And Dialysis Pipeline Will Transform Long Term Revenue Potential

259

88.2% undervalued

AnalystConsensusTarget

4mo ago

Bioengineered Vascular Tissue Platform Will Transform Trauma And Dialysis Care Over The Coming Years

Dialysis Access And Vascular Trauma Challenges Will Eventually Support A Stronger Long Term Outlook

View all narratives

Humacyte, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Humacyte
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.93
52 Haftanın En Yüksek Seviyesi	US$2.93
52 Haftanın En Düşük Seviyesi	US$0.55
Beta	2.31
1 Aylık Değişim	30.96%
3 Aylık Değişim	-7.91%
1 Yıllık Değişim	-58.48%
3 Yıllık Değişim	-77.53%
5 Yıllık Değişim	-90.58%
Halka arzdan bu yana değişim	-90.38%

Son Haberler & Güncellemeler

Recent updates

Seeking Alpha • Feb 09

Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist

Summary Humacyte, Inc. remains rated Hold despite a DoD funding catalyst revealed today, as commercial traction for Symvess is not yet proven. Symvess is the only FDA-approved human-derived bioengineered blood vessel, but Q3 revenue was just $700k, and uptake remains limited. HUMA's funding runway is constrained, with recent capital raises offset by high R&D spending; further dilution or cost cuts may be needed. Key 2026 catalysts are dialysis data readouts and BLA submissions, not the recent DoD news, given ongoing risks and modest near-term sales. Read the full article on Seeking Alpha

Analiz Makalesi • Sep 19

Here's Why Humacyte (NASDAQ:HUMA) Can Afford Some Debt

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Analiz Makalesi • May 21

Is Humacyte (NASDAQ:HUMA) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Seeking Alpha • Mar 24

Humacyte: Symvess' Approval And Launch Are Just The First Steps To Adoption (Downgrade)

Summary Humacyte's stock has dropped 29% since December, despite FDA approval of Symvess. Symvess faces slow adoption due to the need for long-term outcomes data. Humacyte's financial health is precarious, with high operating expenses and a cash runway extending only into late 2025, raising concerns about future dilution. Given these challenges, I downgrade HUMA to "Sell," as achieving a return on investment for Symvess seems unlikely without significant financial strain. Read the full article on Seeking Alpha

Seeking Alpha • Jan 08

Humacyte: Expect A Slow Launch, But Vascular Trauma Indication Is Just A Beginning

Summary Humacyte, Inc. arrived on the Nasdaq in 2021 via a SPAC deal and reappeared on my radar after the Symvess approval in vascular trauma repair. Platform enabling off-the-shelf bioengineered tissues could transform the field of regenerative medicine. There's a large addressable market across 3 lead indications alone (trauma, dialysis & PAD) + significant optionality for more complex projects (i.e., biovascular pancreas in diabetes). Key concerns include slow launch out of the gate, continued cash burn & dilution, competition, and manufacturing capacity. My Action Plan: I remain on the sidelines for HUMA stock and will continue to monitor launch metrics as well as pipeline progress. Read the full article on Seeking Alpha

Seeking Alpha • Dec 23

Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade)

Summary Humacyte stock has dropped 46% since July, mainly due to FDA review delays and mixed Phase 3 trial results for their ATEVs in hemodialysis. Despite FDA approval of Symvess for vascular trauma, its market potential is limited, and adoption is expected to be slow and costly. Phase 3 trial data for ATEVs in hemodialysis patients showed higher thrombosis and infection rates, raising concerns about its safety and efficacy. Humacyte's financial situation remains precarious, with high operating expenses and potential ongoing dilution, leading to a downgrade on HUMA stock from "buy" to "hold". Read the full article on Seeking Alpha

Seeking Alpha • Dec 14

Humacyte: FDA Waiting Game Bleeding Company Dry

Summary Humacyte's innovative ATEV technology shows promise but faces delays in FDA approval, initially expected in Aug, causing financial strain and uncertainty about its market potential. Despite strong clinical data, the FDA's postponement of the ATEV approval has left Humacyte in a precarious financial position, forcing it to raise ~$45m since August. The lack of a clear FDA timeline creates significant risk for investors, leading to a downgrade from "buy" to "hold" due to potential further delays. The market opportunity for ATEVs remains uncertain, questioning whether Humacyte stock can achieve significant upside even if FDA approval is granted. Read the full article on Seeking Alpha

Seeking Alpha • Sep 24

Humacyte: Navigating The FDA Uncertainty And ATEV's Potential

Summary Humacyte’s acellular tissue engineered vessel (ATEV) shows promise in trauma and dialysis, with positive clinical trial results and potential FDA approval by year-end. Despite FDA delays, Humacyte remains optimistic but faces financial instability, with only $43.6 million in cash, supporting operations for 1.5 quarters. HUMA stock is rated as a moderate "Buy" for high-risk tolerant investors, given the potential for FDA approval and significant market capture in trauma. Risks include potential FDA rejection, financial distress, and management's recent share sales, which warrant cautious investment consideration. Read the full article on Seeking Alpha

Analiz Makalesi • Aug 16

Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Jul 17

Humacyte: Pioneering Vascular Solutions With High-Stakes Potential

Summary Humacyte is developing HAVs for multiple indications, showing promising clinical outcomes, and receiving FDA RMAT designation for faster approval processes. The market for vascular repairs is large and growing, with Humacyte's HAVs positioned as a potentially superior option to traditional treatments. Financially, Humacyte holds sufficient short-term assets but faces significant long-term liabilities and a potential cash crunch within a year. I recommend buying HUMA as a speculative, high-risk/high-reward addition to a diversified investment portfolio. Read the full article on Seeking Alpha

Analiz Makalesi • Jun 05

Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation

Key Insights Humacyte's Annual General Meeting to take place on 11th of June Total pay for CEO Laura Niklason includes...

Seeking Alpha • May 14

Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High

Summary Humacyte's stock price has recently been on an impressive bull run, jumping from $4.50 to $6.50 after management announced Q1 2024 earnings. The company's market cap valuation is currently around $765 million - I believe this could rise >$1bn if the company secures a first commercial approval this year, as is likely. Humacyte focuses on regenerative medicine technology, specifically bioengineered human tissues, and has a Biologics License Application accepted by the FDA for its Human Acellular Vessels. The opportunity is in vascular wound treatment, and the FDA has set a decision date for Aug. 10, after awarding a priority review. Humacyte's innovative product that uses a degradable polymer mesh to encourage cell proliferation may be an improvement on current standards of care. Read the full article on Seeking Alpha

Hissedar Getirileri

	HUMA	US Biotechs	US Pazar
7D	-12.3%	-1.6%	-0.3%
1Y	-58.5%	34.3%	24.0%

Getiri vs. Endüstri: HUMA geçen yıl % 34.3 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: HUMA geçen yıl % 24 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is HUMA's price volatile compared to industry and market?
HUMA volatility
HUMA Average Weekly Movement	16.8%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: HUMA hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: HUMA 'nin haftalık oynaklığı ( 17% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2004	184	Laura Niklason	www.humacyte.com

Humacyte, Inc. iştirakleriyle birlikte, birden fazla terapötik alanda çeşitli anatomik konumlardaki hastalıkların ve durumların tedavisi için kullanıma hazır, implante edilebilir ve biyomühendislik ürünü insan dokularının geliştirilmesi ve üretilmesiyle ilgilenmektedir. Şirket, yabancı cisim tepkisine neden olmadan veya bağışıklık reddine yol açmadan hastaya implante edilecek insan aselüler damarlarını (HAV'ler) tasarlamak ve üretmek için tescilli ve bilimsel teknoloji platformunu kullanmaktadır. Vasküler travma, hemodiyaliz için arteriyovenöz erişim, periferik arter hastalığı, pediatrik kalp cerrahisi ve koroner arter baypas greftleme dahil olmak üzere vasküler onarım, rekonstrüksiyon ve replasman pazarını ve Tip 1 diyabeti tedavi etmek için pankreas adacık hücresi nakli de dahil olmak üzere hücresel tedavinin verilmesini hedefleyen bir HAV portföyü geliştirmektedir.

Humacyte, Inc. Temel Bilgiler Özeti

Humacyte'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
HUMA temel i̇stati̇sti̇kler
Piyasa değeri	US$206.50m
Kazançlar(TTM)	-US$95.22m
Gelir(TTM)	US$2.02m

102.4x

P/S Oranı

-2.2x

F/K Oranı

HUMA aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
HUMA gelir tablosu (TTM)
Gelir	US$2.02m
Gelir Maliyeti	US$83.74m
Brüt Kâr	-US$81.72m
Diğer Giderler	US$13.49m
Kazançlar	-US$95.22m

Son Raporlanan Kazançlar

Mar 31, 2026

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.43
Brüt Marj	-4,053.72%
Net Kâr Marjı	-4,723.07%
Borç/Özkaynak Oranı	313.8%

HUMA uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/17 14:33
Gün Sonu Hisse Fiyatı	2026/05/15 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Humacyte, Inc. 9 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Matthew Miksic	Barclays
Bruce Jackson	Benchmark Company
Michael Gorman	BTIG

Humacyte (HUMA) Hisse Özeti

Ödüller

Risk Analizi

Analyst Price Targets

Vascular Trauma And Dialysis Pipeline Will Transform Long Term Revenue Potential

Bioengineered Vascular Tissue Platform Will Transform Trauma And Dialysis Care Over The Coming Years

Dialysis Access And Vascular Trauma Challenges Will Eventually Support A Stronger Long Term Outlook

Top Analyst Narratives

Vascular Trauma And Dialysis Pipeline Will Transform Long Term Revenue Potential

Bioengineered Vascular Tissue Platform Will Transform Trauma And Dialysis Care Over The Coming Years

Dialysis Access And Vascular Trauma Challenges Will Eventually Support A Stronger Long Term Outlook

Humacyte, Inc. Rakipler

NovaBridge Biosciences

Keros Therapeutics

Kazia Therapeutics

Black Diamond Therapeutics

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Price target increased by 10% to US$5.58

No longer forecast to breakeven

New major risk - Financial position

Humacyte Faces Q1 Loss and Workforce Cuts as Symvess Sales and Funding Remain Key

Price target decreased by 68% to US$1.75

Humacyte, Inc. Appoints Todd E. Rasmussen as Chief Surgical Officer

Recent updates

Price target increased by 10% to US$5.58

No longer forecast to breakeven

New major risk - Financial position

Humacyte Faces Q1 Loss and Workforce Cuts as Symvess Sales and Funding Remain Key

Price target decreased by 68% to US$1.75

Humacyte, Inc. Appoints Todd E. Rasmussen as Chief Surgical Officer

Humacyte, Inc. Announces Notice of Non-Compliance with Nasdaq Listing Rule for Common Stock

Humacyte, Inc. to Report Q1, 2026 Results on May 13, 2026

Humacyte, Inc. Announces the Appointment of Jim Mercadante as Chief Commercial Officer

Humacyte, Inc. Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess for Vascular Trauma Repair

Humacyte, Inc., Annual General Meeting, Jun 09, 2026

Consensus revenue estimates decrease by 53%, EPS upgraded

Price target decreased by 7.3% to US$7.29

Humacyte, Inc. Appoints Rick Mcelheny as Senior Vice President of Business Development

Humacyte, Inc. to Report Q4, 2025 Results on Mar 27, 2026

New major risk - Share price stability

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Humacyte, Inc. Submits Marketing Authorization Application For Symvess In Israel For Vascular Trauma Repair

Humacyte, Inc. Announces Presentation of Symvess Long-Term Safety and Efficacy Results At Vess Meeting

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Humacyte: Positive News For Symvess At Last, But Long-Term Threats Persist

Humacyte, Inc. Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Consensus revenue estimates decrease by 29%, EPS upgraded

No longer forecast to breakeven

Price target decreased by 35% to US$5.50

Humacyte, Inc. Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at American Society of Nephrology's Kidney Week 2025

Humacyte, Inc. to Report Q3, 2025 Results on Nov 12, 2025

Humacyte, Inc. Announces Publication of New Data Comparing Symvess to Autologous Vein in Extremity Arterial Trauma

New major risk - Share price stability

Humacyte, Inc. has filed a Follow-on Equity Offering in the amount of $59.999998 million.

Humacyte, Inc. Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Here's Why Humacyte (NASDAQ:HUMA) Can Afford Some Debt

Humacyte, Inc. Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Humacyte, Inc. Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess

Price target decreased by 14% to US$8.43

Consensus revenue estimates fall by 52%

New major risk - Share price stability

Humacyte, Inc. to Report Q2, 2025 Results on Aug 11, 2025

Humacyte, Inc. Announces First Symvess™? Sale to Military Treatment Facility

New major risk - Financial position

Humacyte Announces Symvess ECAT Approval from U.S. Defense Logistics Agency

Humacyte, Inc. Announces the Results from Its V007 Pivotal Phase 3 Clinical Trial of the Acellular Tissue Engineered Vessel

Is Humacyte (NASDAQ:HUMA) A Risky Investment?

New minor risk - Financial position

Humacyte, Inc. to Report Q1, 2025 Results on May 13, 2025

Humacyte, Inc., Annual General Meeting, Jun 10, 2025

Independent Chairman of the Board recently bought US$66k worth of stock

New major risk - Share price stability

Consensus revenue estimates decrease by 16%, EPS upgraded

New major risk - Shareholder dilution

Price target decreased by 8.4% to US$11.71

Humacyte, Inc. has completed a Follow-on Equity Offering in the amount of $50 million.

Humacyte, Inc. to Report Q4, 2024 Results on Mar 28, 2025